Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

A new analysis of 11 global studies shows that people tend to regain lost weight after stopping anti-obesity medications like ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...